Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;56(4):323-335.
doi: 10.1007/s00535-021-01776-1. Epub 2021 Mar 12.

Evidence-based clinical practice guidelines for management of colorectal polyps

Shinji Tanaka  1   2 , Yusuke Saitoh  3 , Takahisa Matsuda  3 , Masahiro Igarashi  3 , Takayuki Matsumoto  3 , Yasushi Iwao  3 , Yasumoto Suzuki  3 , Ryoichi Nozaki  3 , Tamotsu Sugai  3 , Shiro Oka  3 , Michio Itabashi  3 , Ken-Ichi Sugihara  3 , Osamu Tsuruta  3 , Ichiro Hirata  3 , Hiroshi Nishida  3 , Hiroto Miwa  3 , Nobuyuki Enomoto  3 , Tooru Shimosegawa  3 , Kazuhiko Koike  3
Affiliations
Review

Evidence-based clinical practice guidelines for management of colorectal polyps

Shinji Tanaka et al. J Gastroenterol. 2021 Apr.

Abstract

Background: The Japanese Society of Gastroenterology (JSGE) published ''Daicho Polyp Shinryo Guideline 2014'' in Japanese and a part of this guideline was published in English as "Evidence-based clinical practice guidelines for management of colorectal polyps" in the Journal of Gastroenterology in 2015. A revised version of the Japanese-language guideline was published in 2020, and here we introduce a part of the contents of revised version.

Methods: The guideline committee discussed and drew up a series of clinical questions (CQs). Recommendation statements for the CQs were limited to items with multiple therapeutic options. Items with established conclusions that had 100% agreement with previous guidelines (background questions) and items with no (or old) evidence that are topics for future research (future research questions: FRQs) were given descriptions only. To address the CQs and FRQs, PubMed, ICHUSHI, and other sources were searched for relevant articles published in English from 1983 to October 2018 and articles published in Japanese from 1983 to November 2018. The Japan Medical Library Association was also commissioned to search for relevant materials. Manual searches were performed for questions with insufficient online references.

Results: The professional committee created 18 CQs and statements concerning the current concept and diagnosis/treatment of various colorectal polyps, including their epidemiology, screening, pathophysiology, definition and classification, diagnosis, management, practical treatment, complications, and surveillance after treatment, and other colorectal lesions (submucosal tumors, nonneoplastic polyps, polyposis, hereditary tumors, ulcerative colitis-associated tumors/carcinomas).

Conclusions: After evaluation by the moderators, evidence-based clinical practice guidelines for management of colorectal polyps were proposed for 2020. This report addresses the therapeutic related CQs introduced when formulating these guidelines.

Keywords: Colorectal polyp; Colorectal tumor; Minds guidelines; Polyposis; Treatment.

PubMed Disclaimer

Conflict of interest statement

Any financial relationship with enterprises, businesses or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows; (1) those from which the authors, the spouse, partner or immediate relatives of authors, have received individually any income, honoraria or any other types of remuneration; Olympus Corporation, Astellas Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Pfizer, and (2) those from which the academic institutions of the authors received support (commercial/academic cooperation); Taiho Pharmaceutical, Tsumura & Co., Bristol Myers Squibb, Astellas Pharmaceutical, Abbvie, EA Pharma, Eisai, MSD, Ono Pharmaceutical, CSL Behring, Johnson & Johnson, Mochida Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Japan Blood Products Organization, Novartis Pharma, Bayer Japan, Merck Biopharma, Asahi Kasei Pharma.

References

    1. Daicho Polyp Sinryo Guidelines 2020 from the Japanese Society of Gastroenterology (JSGE), Nankodo, Tokyo, 2020 (in Japanese)
    1. Tanaka S, Saitoh Y, Matsuda T, at al. Evidence-based clinical practice guidelines for management of colorectal polyps. J Gastroenterol. 2015: 50: 252–260 - PubMed
    1. Morizane T, Yoshida M, Kojimahara N, editors. Minds Handbook for Clinical Practice Guideline Development 2014. Japan Council for Quality Health Care: Tokyo, Japan; 2015.
    1. Yoshida M, Kinoshita Y, Watanabe M, et al. JSGE clinical practice guidelines 2014; standards, methods, and process of developing the guidelines. J Gastroenterol. 2015;50:4–10. - PubMed
    1. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977–1981. - PubMed